Recent 8-K filings for CLDX

• May 7, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Celldex completes Phase 3 CSU enrollment 6 months early; raises $345M; Q1 net loss $78.7M

  Phase 3 CSU (EMBARQ-CSU1/2) enrolled 1,939 patients, 6 months ahead of guidance; topline data expected Q4 2026, BLA in 2027.

• April 2, 2026, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 8.01item 9.01 ◈ Material Agreements

  Celldex prices $300M public offering of 10.3M shares at $29.00 for pipeline and barzolvolimab launch

  Priced underwritten public offering of 10,345,000 shares at $29.00/share; gross proceeds ~$300M.

• February 25, 2026, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Celldex completes Phase 3 CSU enrollment six months early; cash $518.6M; net loss $1.22/sh Q4

  Phase 3 CSU program enrolled 1,939 patients across 43 countries; topline data expected Q4 2026, BLA filing planned 2027.

• November 10, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Celldex Q3 net loss $67M; barzolvolimab Phase 2 data positive in urticarias

  Net loss of $67.0M ($1.01/share) vs $42.1M in Q3 2024; cash use $48.6M in operations.

• August 19, 2025, 7:59 PM ET other material materiality 0.75 negative item 8.01item 9.01

  Celldex Phase 2 barzolvolimab in EoE meets primary endpoint but no clinical benefit; advancement stopped

  Primary endpoint met: peak mast cell count reduced by -36.0 vs placebo -2.7 (p<0.0001) at Week 12.

• August 7, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Celldex Q2 net loss $56.6M ($0.85/share); cash $630.3M; barzolvolimab shows durable complete response at 76 weeks

  Net loss of $56.6M versus $35.8M in Q2 2024; R&D spend rose to $54.2M on barzolvolimab trials.

• May 8, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Celldex Q1 net loss widens to $53.8M; Phase 3 CSU enrollment ongoing, multiple data readouts in 2025

  Net loss of $53.8M ($0.81/share) vs $32.8M ($0.56/share) in Q1 2024; R&D expenses rose to $52.6M.

• February 27, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Celldex reports Q4 2024 net loss of $47.1M; cash $725.3M; Phase 3 CSU studies enrolling

  Cash, equivalents and securities $725.3M at Dec 31, 2024; company funded through 2027.

• November 6, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Celldex Q3 net loss $42.1M; barzolvolimab meets Phase 2 CIndU endpoints

  Net loss of $42.1M ($0.64 per share) vs $38.3M in Q3 2023; revenue $3.2M vs $1.5M.

• August 8, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Celldex Q2 net loss $0.54 per share; Phase 3 CSU program launched

  Net loss $35.8M ($0.54/share) vs $30.5M loss in Q2 2023; revenue $2.5M, up from $0.3M.

• May 6, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Celldex reports Q1 net loss $32.8M; cash $823.8M; Phase 3 CSU studies planned summer 2024

  Net loss of $32.8M ($0.56 per share) vs $29.4M ($0.62) in Q1 2023; revenue $0.2M.

• March 1, 2024, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 8.01item 9.01 ◈ Material Agreements

  Celldex prices upsized $400M common stock offering at $47/share, net proceeds ~$376M

  Priced public offering of 8,520,000 shares at $47.00 per share; upsized from initial $250M to $400M.

• February 26, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Celldex Q4 2023 net loss $43.3M; cash $423.6M; Phase 3 CSU study planned for summer 2024

  Q4 2023 net loss $43.3M ($0.83/share) vs $26.5M ($0.56) in Q4 2022; FY net loss $141.4M ($2.92/share).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.70 · Most common event earnings

6 positive 1 negative 8 neutral

source · CLDX on sec.gov